Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
GLOBENEWSWIRE 10:38 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.7084down -0.1316 (-7.1522%)
QUOTES AS OF 10:37:41 AM ET 02/28/2023
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) (“Amarin” or the “Company”) today announced that, based on the preliminary voting results provided by its proxy solicitors following the Company’s 2023 General Meeting of Shareholders (the “General Meeting”), Amarin(AMRN) shareholders have voted to elect all seven of Sarissa’s nominees and remove Per Wold-Olsen as Chairman of the Board of Directors, effective immediately.
Amarin’s reconstituted Board will be expanded to 15 directors – Adam Berger, Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Erin Enright, Keith Horn, Jan van Heek, Odysseas Kostas, Karim Mikhail, Geraldine Murphy, Kristine Peterson, Louis Sterling, Dr. Murray Stewart, Diane Sullivan and Alfonso “Chito” Zulueta. The Board will appoint a new Chairman in due course.
Amarin (AMRN) issued the following statement:
Amarin (AMRN) appreciates the engagement with our shareholders, as well as the valuable insights and perspectives they have shared throughout this process.
While we sought a different outcome, the Board and management team remain focused on executing Amarin’s strategy, particularly at this critical juncture with ongoing pricing and reimbursement negotiations in Europe, International expansion efforts and continued stabilization of our U.S. business, to deliver near- and long-term value. We will work constructively with the newly elected directors toward these shared goals.
We thank Per Wold-Olsen for his unwavering leadership, dedication and oversight during his tenure on the Board and while serving as Chairman.
The election results announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections. Final results will be reported on a Form 8-K that will be filed with the Securities and Exchange Commission.
Advisors
J.P. Morgan is acting as financial advisor. Ropes & Gray LLP and Goodwin Procter LLP are acting as legal advisors to the Company.
About Amarin(AMRN)
Amarin (AMRN) is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in
